Marker Therapeutics, Inc. has announced a collaboration with Cellipont Bioservices to support the cGMP manufacturing of MT-601, its lead Multi-Antigen Recognizing (MAR)-T cell therapy, currently in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results